RT Journal Article
SR Electronic
T1 The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP 63
DO 10.1186/s40425-017-0268-8
VO 5
IS 1
A1 Poon, Edmund
A1 Mullins, Stefanie
A1 Watkins, Amanda
A1 Williams, Geoffrey S.
A1 Koopmann, Jens-Oliver
A1 Di Genova, Gianfranco
A1 Cumberbatch, Marie
A1 Veldman-Jones, Margaret
A1 Grosskurth, Shaun E.
A1 Sah, Vasu
A1 Schuller, Alwin
A1 Reimer, Corrine
A1 Dovedi, Simon J.
A1 Smith, Paul D.
A1 Stewart, Ross
A1 Wilkinson, Robert W.
YR 2017
UL http://jitc.bmj.com/content/5/1/63.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.